secwatch / observer

8-K filed May 27, 2026, 8:30 AM ET ticker BIAF CIK 0001712762

other material confidence high sentiment positive materiality 0.50

bioAffinity Technologies announces Mexican patent allowance for CyPath Lung cancer detection method

bioAffinity Technologies, Inc.

Mexican patent allowance for flow-cytometry methods to detect lung cancer using CyPath Lung.
Patent will protect use of defined antibodies and TCPP porphyrin to label sputum cells.
CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in trial.
IP portfolio now includes patents in US, EU, China, Japan, Australia, Canada, and Mexico.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-025338
form_type: 8-K
ticker: BIAF
cik: 0001712762
company_name: bioAffinity Technologies, Inc.
filed_at: 2026-05-27T12:30:16+00:00
discovered_at: 2026-05-27T12:35:01.404678+00:00
generated_at: 2026-05-27T12:36:46.126135+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-025338
json_url: https://secwatch.observer/filing/0001493152-26-025338.json
markdown_url: https://secwatch.observer/filing/0001493152-26-025338.md
text_url: https://secwatch.observer/filing/0001493152-26-025338.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315226025338/0001493152-26-025338-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315226025338/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

GIPR

Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit

GENERATION INCOME PROPERTIES, INC. June 1, 2026, 5:27 PM ET other_material Items 1.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

MUX

McEwen receives $49.4M dividend from Minera Santa Cruz; total 2026 dividends now $58.2M

McEwen Inc. June 1, 2026, 5:14 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EMYB

Embassy Bancorp expands stock repurchase program by additional $5M

Embassy Bancorp, Inc. June 1, 2026, 4:37 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTXR

Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned

Citius Pharmaceuticals, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ORKA

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends

Via Renewables, Inc. June 1, 2026, 3:06 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001493152-26-025338

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.